Findings

What do systematic reviews say?

28 questions · 29 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 3.4%GRADE not reported 0 · 0%Very low 7 · 24.1%Low 11 · 37.9%Moderate 10 · 34.5%High 0 · 0%

Intravenous ± oral steroids vs oral steroids alone

Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome

It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 4.75]
1 study · 22 participants
Very low

Intravenous ± oral steroids vs oral steroids alone

Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome

It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.13 [0.15, 0.4]
1 study · 18 participants
Very low

Intravenous ± oral steroids vs oral steroids alone

Complete remission · minimal change disease in adults with nephrotic syndrome

It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.76 [0.17, 18.32]
2 studies · 35 participants
Very low

Intravenous ± oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous ± oral steroids vs oral steroids alone

Relapse · minimal change disease in adults with nephrotic syndrome

It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.18 [0.65, 2.15]
1 study · 19 participants
Very low

Mycophenolate sodium + oral steroids vs oral steroids alone

Complete remission · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).

2 findings from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.12 [0.84, 1.5]
1 study · 114 participants
Moderate
Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.08 [0.84, 1.38]
2 studies · 134 participants
Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.92 [0.75, 1.12]
2 studies · 134 participants
Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Relapse · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.43 [0.08, 2.25]
2 studies · 80 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Adverse events: death · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.84]
1 study · 116 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Acute kidney injury · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.36]
1 study · 116 participants
Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Adverse events: new‐onset glucose intolerance · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.2 [0.01, 4.08]
2 studies · 136 participants
Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Complete remission · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.99 [0.93, 1.05]
8 studies · 492 participants
Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.05]
4 studies · 269 participants
Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Relapse · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in relapse Time frame: 6 to 12 months compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.73 [0.51, 1.03]
7 studies · 422 participants
Moderate

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Adverse effects: diabetes or hyperglycaemia · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: diabetes or hyperglycaemia compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.48 [0.19, 1.25]
7 studies · 450 participants
Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Adverse effects: obesity or Cushing's Syndrome · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: obesity or Cushing's Syndrome compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.11 [0.02, 0.59]
5 studies · 388 participants
Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Adverse events: hypertension · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: hypertension compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.86 [0.23, 3.2]
3 studies · 219 participants
Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Acute kidney injury · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.78 [0.35, 8.99]
4 studies · 270 participants
Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Adverse effects: acne · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: acne compared with oral steroids alone (low certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.15 [0.03, 0.67]
4 studies · 270 participants
Low

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).

1 finding from 1 review

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes only
RR 0.76 [0.25, 2.3]
7 studies · 440 participants
Low